Importer of Controlled Substances Registration, 14913-14914 [2017-05730]
Download as PDF
<![CDATA[
14913
Federal Register / Vol. 82, No. 55 / Thursday, March 23, 2017 / Notices
INTERNATIONAL TRADE
COMMISSION
[USITC SE–17–012]
Government in the Sunshine Act
Meeting Notice
United
States International Trade Commission.
TIME AND DATE: March 30, 2017 at 11:00
a.m.
PLACE: Room 101, 500 E Street SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
AGENCY HOLDING THE MEETING:
Matters To Be Considered
1. Agendas for future meetings: None.
2. Minutes.
3. Ratification List.
4. Vote in Inv. No. 731–TA–1314
(Final) (Phosphor Copper from Korea).
The Commission is currently scheduled
to complete and file its determination
and views of the Commission by April
17, 2017.
5. Outstanding action jackets: None.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
By order of the Commission.
Issued: March 21, 2017.
William R. Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2017–05893 Filed 3–21–17; 4:15 pm]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Registration
ACTION:
Registrants listed below have
applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as bulk
manufacturers of various classes of
controlled substances.
SUPPLEMENTARY INFORMATION:
The companies listed below applied
to be registered as manufacturers of
various basic classes of controlled
substances. Information on previously
published notices is listed in the table
below. No comments or objections were
submitted for these notices.
SUMMARY:
Company
FR docket
sradovich on DSK3GMQ082PROD with NOTICES
Noramco, Inc .................................................................................................................................................
Isosciences ....................................................................................................................................................
AMRI Rensselaer, Inc ...................................................................................................................................
Halo Pharmaceutical, Inc ..............................................................................................................................
AMPAC Fine Chemicals LLC ........................................................................................................................
Insys Manufacturing LLC ..............................................................................................................................
Patheon API Manufacturing, Inc ...................................................................................................................
Euticals Inc ....................................................................................................................................................
Nanosyn, Inc .................................................................................................................................................
Cerilliant Corporation .....................................................................................................................................
Research Triangle Institute ...........................................................................................................................
Synthcon LLC ................................................................................................................................................
Navinta LLC ...................................................................................................................................................
Johnson Matthey, Inc ....................................................................................................................................
AMRI Rensselaer, Inc ...................................................................................................................................
Cayman Chemical Company ........................................................................................................................
Cambridge Isotope Laboratories ...................................................................................................................
Janssen Pharmaceutical, Inc ........................................................................................................................
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of these registrants to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated each of the company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
VerDate Sep<11>2014
17:13 Mar 22, 2017
Jkt 241001
Notice of registration.
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed persons.
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
81
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
57936
61249
61250
63220
63222
63221
64509
64510
64949
66079
91948
95641
95640
95647
95639
95644
95644
96045
Published
August 24, 2016.
September 6, 2016.
September 6, 2016.
September 14, 2016.
September 14, 2016.
September 14, 2016.
September 20, 2016.
September 20, 2016.
September 21, 2016.
September 26, 2016.
December 19, 2016.
December 28, 2016.
December 28, 2016.
December 28, 2016.
December 28, 2016.
December 28, 2016.
December 28, 2016.
December 29, 2016.
Dated: March 17, 2017.
Louis J. Milione,
Assistant Administrator.
Registrants listed below have
applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as importers of
various classes of schedule I or II
controlled substances.
[FR Doc. 2017–05727 Filed 3–22–17; 8:45 am]
SUPPLEMENTARY INFORMATION:
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
ACTION:
PO 00000
SUMMARY:
The
companies listed below applied to be
registered as importers of various basic
classes of controlled substances.
Information on previously published
notices is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for these notices.
Notice of registration.
Frm 00049
Fmt 4703
Sfmt 4703
E:\FR\FM\23MRN1.SGM
23MRN1
14914
Federal Register / Vol. 82, No. 55 / Thursday, March 23, 2017 / Notices
Company
FR docket
Fisher Clinical Services, Inc ..........................................................................................................................
Sigma-Aldrich International:
GMBH-Sigma Aldrich Company LLC .....................................................................................................
Fisher Clinical Services, Inc ...................................................................................................................
Anderson Brecon, Inc ............................................................................................................................
Johnson Matthey Inc ..............................................................................................................................
Wildlife Laboratories, Inc ........................................................................................................................
Noramco, Inc ..........................................................................................................................................
Mylan Technologies, Inc ........................................................................................................................
81 FR 61248
September 6, 2016.
81
81
81
81
81
81
82
September 14, 2016.
October 4, 2016.
October 18, 2016.
October 18, 2016.
December 28, 2016.
December 28, 2016.
January 23, 2017.
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of the
listed registrants to import the
applicable basic classes of schedule I or
II controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated each company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I or II controlled substances to
the above listed persons.
Dated: March 17, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017–05730 Filed 3–22–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Wildlife Laboratories, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before April 24, 2017. Such persons
may also file a written request for a
hearing on the application pursuant to
21 CFR 1301.43 on or before April 24,
2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
DATES:
FR
FR
FR
FR
FR
FR
FR
63223
68455
71766
71766
95644
95640
7859
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on
February 2, 2017, Wildlife Laboratories,
Inc., 1230 W. Ash Street, Suite D,
Windsor, Colorado 80550–8055 applied
to be registered as an importer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
Etorphine (except HCl) ............................................................................................................................................
Etorphine HCl ..........................................................................................................................................................
Thiafentanil ..............................................................................................................................................................
sradovich on DSK3GMQ082PROD with NOTICES
The company plans to import the
listed controlled substances for sale to
its customers.
DEPARTMENT OF LABOR
Dated: March 17, 2017.
Louis J. Milione,
Assistant Administrator.
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; FederalState Unemployment Insurance
Program Data Exchange
Standardization
[FR Doc. 2017–05729 Filed 3–22–17; 8:45 am]
BILLING CODE 4410–09–P
Office of the Secretary
ACTION:
Notice.
18:27 Mar 22, 2017
Jkt 241001
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Schedule
9056
9059
9729
I
II
II
and Training Administration (ETA)
sponsored information collection
request (ICR) titled, ‘‘Federal-State
Unemployment Insurance Program Data
Exchange Standardization,’’ to the
Office of Management and Budget
(OMB) for review and approval for
continued use, without change, in
accordance with the Paperwork
Reduction Act of 1995 (PRA). Public
comments on the ICR are invited.
The OMB will consider all
written comments that agency receives
on or before April 24, 2017.
DATES:
The Department of Labor
(DOL) is submitting the Employment
SUMMARY:
VerDate Sep<11>2014
Published
E:\FR\FM\23MRN1.SGM
23MRN1
]]>Agencies
[Federal Register Volume 82, Number 55 (Thursday, March 23, 2017)]
[Notices]
[Pages 14913-14914]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05730]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Registration
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Registrants listed below have applied for and been granted
registration by the Drug Enforcement Administration (DEA) as importers
of various classes of schedule I or II controlled substances.
SUPPLEMENTARY INFORMATION: The companies listed below applied to be
registered as importers of various basic classes of controlled
substances. Information on previously published notices is listed in
the table below. No comments or objections were submitted and no
requests for hearing were submitted for these notices.
[[Page 14914]]
----------------------------------------------------------------------------------------------------------------
Company FR docket Published
----------------------------------------------------------------------------------------------------------------
Fisher Clinical Services, Inc............ 81 FR 61248 September 6, 2016.
Sigma-Aldrich International: ......................................
GMBH-Sigma Aldrich Company LLC....... 81 FR 63223 September 14, 2016.
Fisher Clinical Services, Inc........ 81 FR 68455 October 4, 2016.
Anderson Brecon, Inc................. 81 FR 71766 October 18, 2016.
Johnson Matthey Inc.................. 81 FR 71766 October 18, 2016.
Wildlife Laboratories, Inc........... 81 FR 95644 December 28, 2016.
Noramco, Inc......................... 81 FR 95640 December 28, 2016.
Mylan Technologies, Inc.............. 82 FR 7859 January 23, 2017.
----------------------------------------------------------------------------------------------------------------
The DEA has considered the factors in 21 U.S.C. 823, 952(a) and
958(a) and determined that the registration of the listed registrants
to import the applicable basic classes of schedule I or II controlled
substances is consistent with the public interest and with United
States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971. The DEA investigated each company's
maintenance of effective controls against diversion by inspecting and
testing each company's physical security systems, verifying each
company's compliance with state and local laws, and reviewing each
company's background and history.
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the DEA has granted a registration as
an importer for schedule I or II controlled substances to the above
listed persons.
Dated: March 17, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017-05730 Filed 3-22-17; 8:45 am]
BILLING CODE 4410-09-P
